2024-11-012025-10-312025-10-31false07615494AGAPE CARE SOLUTIONS LTD2026-10-0886900falseiso4217:GBPxbrli:pure076154942024-10-31076154942025-10-31076154942024-11-012025-10-31076154942023-04-30076154942024-10-31076154942023-05-012024-10-3107615494bus:SmallEntities2024-11-012025-10-3107615494bus:AuditExempt-NoAccountantsReport2024-11-012025-10-3107615494bus:FullAccounts2024-11-012025-10-3107615494bus:PrivateLimitedCompanyLtd2024-11-012025-10-3107615494core:WithinOneYear2025-10-3107615494core:AfterOneYear2025-10-3107615494core:WithinOneYear2024-10-3107615494core:AfterOneYear2024-10-3107615494core:ShareCapital2025-10-3107615494core:SharePremium2025-10-3107615494core:RevaluationReserve2025-10-3107615494core:OtherReservesSubtotal2025-10-3107615494core:RetainedEarningsAccumulatedLosses2025-10-3107615494core:ShareCapital2024-10-3107615494core:SharePremium2024-10-3107615494core:RevaluationReserve2024-10-3107615494core:OtherReservesSubtotal2024-10-3107615494core:RetainedEarningsAccumulatedLosses2024-10-3107615494core:LandBuildings2025-10-3107615494core:PlantMachinery2025-10-3107615494core:Vehicles2025-10-3107615494core:FurnitureFittings2025-10-3107615494core:OfficeEquipment2025-10-3107615494core:NetGoodwill2025-10-3107615494core:IntangibleAssetsOtherThanGoodwill2025-10-3107615494core:ListedExchangeTraded2025-10-3107615494core:UnlistedNon-exchangeTraded2025-10-3107615494core:LandBuildings2024-10-3107615494core:PlantMachinery2024-10-3107615494core:Vehicles2024-10-3107615494core:FurnitureFittings2024-10-3107615494core:OfficeEquipment2024-10-3107615494core:NetGoodwill2024-10-3107615494core:IntangibleAssetsOtherThanGoodwill2024-10-3107615494core:ListedExchangeTraded2024-10-3107615494core:UnlistedNon-exchangeTraded2024-10-3107615494core:LandBuildings2024-11-012025-10-3107615494core:PlantMachinery2024-11-012025-10-3107615494core:Vehicles2024-11-012025-10-3107615494core:FurnitureFittings2024-11-012025-10-3107615494core:OfficeEquipment2024-11-012025-10-3107615494core:NetGoodwill2024-11-012025-10-3107615494core:IntangibleAssetsOtherThanGoodwill2024-11-012025-10-3107615494core:ListedExchangeTraded2024-11-012025-10-3107615494core:UnlistedNon-exchangeTraded2024-11-012025-10-3107615494core:MoreThanFiveYears2024-11-012025-10-3107615494core:Non-currentFinancialInstruments2025-10-3107615494core:Non-currentFinancialInstruments2024-10-3107615494dpl:CostSales2024-11-012025-10-3107615494dpl:DistributionCosts2024-11-012025-10-3107615494core:LandBuildings2024-11-012025-10-3107615494core:PlantMachinery2024-11-012025-10-3107615494core:Vehicles2024-11-012025-10-3107615494core:FurnitureFittings2024-11-012025-10-3107615494core:OfficeEquipment2024-11-012025-10-3107615494dpl:AdministrativeExpenses2024-11-012025-10-3107615494core:NetGoodwill2024-11-012025-10-3107615494core:IntangibleAssetsOtherThanGoodwill2024-11-012025-10-3107615494dpl:GroupUndertakings2024-11-012025-10-3107615494dpl:ParticipatingInterests2024-11-012025-10-3107615494dpl:GroupUndertakingscore:ListedExchangeTraded2024-11-012025-10-3107615494core:ListedExchangeTraded2024-11-012025-10-3107615494dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-11-012025-10-3107615494core:UnlistedNon-exchangeTraded2024-11-012025-10-3107615494dpl:CostSales2023-05-012024-10-3107615494dpl:DistributionCosts2023-05-012024-10-3107615494core:LandBuildings2023-05-012024-10-3107615494core:PlantMachinery2023-05-012024-10-3107615494core:Vehicles2023-05-012024-10-3107615494core:FurnitureFittings2023-05-012024-10-3107615494core:OfficeEquipment2023-05-012024-10-3107615494dpl:AdministrativeExpenses2023-05-012024-10-3107615494core:NetGoodwill2023-05-012024-10-3107615494core:IntangibleAssetsOtherThanGoodwill2023-05-012024-10-3107615494dpl:GroupUndertakings2023-05-012024-10-3107615494dpl:ParticipatingInterests2023-05-012024-10-3107615494dpl:GroupUndertakingscore:ListedExchangeTraded2023-05-012024-10-3107615494core:ListedExchangeTraded2023-05-012024-10-3107615494dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-05-012024-10-3107615494core:UnlistedNon-exchangeTraded2023-05-012024-10-3107615494core:NetGoodwill2025-10-3107615494core:IntangibleAssetsOtherThanGoodwill2025-10-3107615494core:LandBuildings2025-10-3107615494core:PlantMachinery2025-10-3107615494core:Vehicles2025-10-3107615494core:FurnitureFittings2025-10-3107615494core:OfficeEquipment2025-10-3107615494core:AfterOneYear2025-10-3107615494core:WithinOneYear2025-10-3107615494core:ListedExchangeTraded2025-10-3107615494core:UnlistedNon-exchangeTraded2025-10-3107615494core:ShareCapital2025-10-3107615494core:SharePremium2025-10-3107615494core:RevaluationReserve2025-10-3107615494core:OtherReservesSubtotal2025-10-3107615494core:RetainedEarningsAccumulatedLosses2025-10-3107615494core:NetGoodwill2024-10-3107615494core:IntangibleAssetsOtherThanGoodwill2024-10-3107615494core:LandBuildings2024-10-3107615494core:PlantMachinery2024-10-3107615494core:Vehicles2024-10-3107615494core:FurnitureFittings2024-10-3107615494core:OfficeEquipment2024-10-3107615494core:AfterOneYear2024-10-3107615494core:WithinOneYear2024-10-3107615494core:ListedExchangeTraded2024-10-3107615494core:UnlistedNon-exchangeTraded2024-10-3107615494core:ShareCapital2024-10-3107615494core:SharePremium2024-10-3107615494core:RevaluationReserve2024-10-3107615494core:OtherReservesSubtotal2024-10-3107615494core:RetainedEarningsAccumulatedLosses2024-10-3107615494core:NetGoodwill2023-04-3007615494core:IntangibleAssetsOtherThanGoodwill2023-04-3007615494core:LandBuildings2023-04-3007615494core:PlantMachinery2023-04-3007615494core:Vehicles2023-04-3007615494core:FurnitureFittings2023-04-3007615494core:OfficeEquipment2023-04-3007615494core:AfterOneYear2023-04-3007615494core:WithinOneYear2023-04-3007615494core:ListedExchangeTraded2023-04-3007615494core:UnlistedNon-exchangeTraded2023-04-3007615494core:ShareCapital2023-04-3007615494core:SharePremium2023-04-3007615494core:RevaluationReserve2023-04-3007615494core:OtherReservesSubtotal2023-04-3007615494core:RetainedEarningsAccumulatedLosses2023-04-3007615494core:AfterOneYear2024-11-012025-10-3107615494core:WithinOneYear2024-11-012025-10-3107615494core:Non-currentFinancialInstrumentscore:CostValuation2024-11-012025-10-3107615494core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-11-012025-10-3107615494core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-11-012025-10-3107615494core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-11-012025-10-3107615494core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-11-012025-10-3107615494core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-11-012025-10-3107615494core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-11-012025-10-3107615494core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-11-012025-10-3107615494core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-11-012025-10-3107615494core:Non-currentFinancialInstrumentscore:CostValuation2025-10-3107615494core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-10-3107615494core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-10-3107615494core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-10-3107615494core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-10-3107615494core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-10-3107615494core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-10-3107615494core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-10-3107615494core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-10-3107615494core:Non-currentFinancialInstrumentscore:CostValuation2024-10-3107615494core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-10-3107615494core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-10-3107615494core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-10-3107615494core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-10-3107615494core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-10-3107615494core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-10-3107615494core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-10-3107615494core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-10-3107615494bus:Director12024-11-012025-10-31076154941bus:Director12024-10-31076154941bus:Director12024-11-012025-10-31076154941bus:Director12025-10-31076154942024-10-31076154942024-11-012025-10-31076154942025-10-310761549412024-11-012025-10-31

AGAPE CARE SOLUTIONS LTD

Registered Number
07615494
(England and Wales)

Unaudited Financial Statements for the Year ended
31 October 2025

AGAPE CARE SOLUTIONS LTD
Company Information
for the year from 1 November 2024 to 31 October 2025

Director

MRS A BARKER

Registered Address

369-371 Ashley Road
Poole
BH14 0AS

Registered Number

07615494 (England and Wales)
AGAPE CARE SOLUTIONS LTD
Balance Sheet as at
31 October 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets20,49265,177
20,49265,177
Current assets
Debtors4,5381,125250,034
Cash at bank and on hand4,56517
385,690250,051
Creditors amounts falling due within one year6(562,794)(314,745)
Net current assets (liabilities)(177,104)(64,694)
Total assets less current liabilities(156,612)483
Creditors amounts falling due after one year7-(34,604)
Net assets(156,612)(34,121)
Capital and reserves
Called up share capital22
Profit and loss account(156,614)(34,123)
Shareholders' funds(156,612)(34,121)
The financial statements were approved and authorised for issue by the Director on 8 October 2026, and are signed on its behalf by:
MRS A BARKER
Director
Registered Company No. 07615494
AGAPE CARE SOLUTIONS LTD
Notes to the Financial Statements
for the year ended 31 October 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Going concern
31 October 2025, the company had significant amounts outstanding to creditors, including HM Revenue & Customs, and was experiencing cash flow difficulties. Subsequent to the year end, the directors sought to restructure the company's liabilities through a Company Voluntary Arrangement ("CVA"). The CVA was approved by the company's creditors in April 2026 and included debts totalling approximately £572,000, including associated professional fees. The directors have prepared forecasts and projections for a period of at least twelve months from the date of approval of these financial statements. These forecasts take into account the company's ongoing trading activities, anticipated cash flows and the payment obligations arising under the CVA. On the basis of these forecasts, the directors have a reasonable expectation that the company will have sufficient resources to continue in operational existence and to meet its obligations under the CVA as they fall due. Accordingly, the directors consider it appropriate to prepare the financial statements on a going concern basis.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the rendering of services.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Reducing balance (%)
Plant and machinery25
Vehicles25
Finance leases and hire purchase contracts
Assets held under finance leases which are leases where substantially all the risks and rewards of ownership of the asset have passed to the company, and hire purchase contracts are capitalised in the balance sheet. They are depreciated over the shorter of their useful lives or the term of the lease.
2.Average number of employees

20252024
Average number of employees during the year4337
3.Prior period adjustment
During the year, the company identified that research and development tax credits recognised in a previous accounting period included amounts which were subsequently determined to be repayable to HM Revenue & Customs. The financial statements have therefore been restated to recognise an additional liability to HM Revenue & Customs of £25,000, with a corresponding adjustment to reserves by increasing retained losses carried forward.
4.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables160,654150,841
Other debtors101,01423,579
Prepayments and accrued income-1,500
Total261,668175,920
5.Debtors: amounts due after one year

2025

2024

££
Other debtors119,45774,114
Total119,45774,114
6.Creditors: amounts due within one year

2025

2024

££
Bank borrowings and overdrafts70,83960,057
Taxation and social security453,871194,988
Finance lease and HP contracts-30,944
Other creditors28,48427,346
Accrued liabilities and deferred income9,6001,410
Total562,794314,745
7.Creditors: amounts due after one year

2025

2024

££
Bank borrowings and overdrafts-18,225
Other creditors-16,379
Total-34,604
8.Obligations under finance leases

2025

2024

££
Finance lease and HP contracts-47,324
9.Directors advances, credits and guarantees

Brought forward

Amount advanced

Amount repaid

Carried forward

££££
MRS A BARKER0119,4570119,457
0119,4570119,457
During the year, the company made a loan to the director. The amount outstanding at 31 October 2025 was £119,457 and remained outstanding at the date of approval of these financial statements. Interest amounting to £3,602 was charged on the outstanding loan balance during the year, based on the HMRC official rate of interest, as applicable. The balance is unsecured and repayable on demand.
10.Events after reporting date
Subsequent to the year end, in May 2026, the company's creditors approved a Company Voluntary Arrangement. The total debts subject to the arrangement, including associated professional costs, were approximately £572,000. These included amounts due to HM Revenue & Customs, including approximately £25,000 relating to the repayment of previously claimed research and development tax relief. The CVA was not approved at the balance sheet date and accordingly the financial statements do not reflect any subsequent compromise of creditors arising under the arrangement.